KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.87 $1.65 Friday, 26th Apr 2024 ADAP stock ended at $1.08. This is 1.42% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 5.83% from a day low at $1.03 to a day high of $1.09.
90 days $0.730 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Oct 26, 2022 $1.23 $1.36 $1.22 $1.34 597 700
Oct 25, 2022 $1.03 $1.27 $1.02 $1.27 833 528
Oct 24, 2022 $1.28 $1.28 $1.18 $1.20 729 913
Oct 21, 2022 $1.32 $1.41 $1.26 $1.28 4 925 066
Oct 20, 2022 $1.24 $1.42 $1.22 $1.31 448 851
Oct 19, 2022 $1.16 $1.25 $1.14 $1.23 479 446
Oct 18, 2022 $1.14 $1.22 $1.14 $1.17 146 242
Oct 17, 2022 $1.13 $1.22 $1.09 $1.16 225 319
Oct 14, 2022 $1.12 $1.17 $1.09 $1.13 143 540
Oct 13, 2022 $1.05 $1.13 $1.02 $1.12 172 293
Oct 12, 2022 $1.08 $1.09 $1.03 $1.05 153 280
Oct 11, 2022 $1.08 $1.18 $1.03 $1.09 212 601
Oct 10, 2022 $1.19 $1.19 $1.08 $1.09 469 682
Oct 07, 2022 $1.13 $1.23 $1.06 $1.20 616 776
Oct 06, 2022 $1.12 $1.16 $1.08 $1.12 196 887
Oct 05, 2022 $1.14 $1.16 $1.09 $1.10 313 986
Oct 04, 2022 $1.09 $1.20 $1.08 $1.15 274 235
Oct 03, 2022 $1.05 $1.16 $1.03 $1.08 332 799
Sep 30, 2022 $1.08 $1.09 $1.01 $1.08 317 128
Sep 29, 2022 $1.15 $1.16 $1.02 $1.06 597 620
Sep 28, 2022 $1.10 $1.19 $1.09 $1.15 528 532
Sep 27, 2022 $1.20 $1.24 $1.09 $1.11 584 206
Sep 26, 2022 $1.16 $1.24 $1.16 $1.20 270 213
Sep 23, 2022 $1.35 $1.40 $1.10 $1.17 1 155 076
Sep 22, 2022 $1.36 $1.40 $1.29 $1.33 246 961
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT